Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06876883

MItral Regurgitation Risk Assessment and CLinical modElling

MItral Regurgitation Risk Assessment and CLinical modElling (MIRACLE Study)

Status
Recruiting
Phase
Study type
Observational
Enrollment
2,000 (estimated)
Sponsor
Sun Yat-sen University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Mitral regurgitation (MR) is a common valvular heart disease worldwide, and untreated severe MR is associated with an elevated risk of heart failure and mortality. According to causes, MR could be divided into primary or secondary MR. The risk factors of mortality or heart failure hospitalization in different types of MR patients are under intensive investigation. MItral Regurgitation risk Assessment and CLinical modElling (MIRACLE) study is a prospective cohort study including adult patients diagnosed with ≥ moderate MR during hospitalization. Comprehensive echocardiographic examination was conducted at baseline evaluating valvular heart disease severity, atrial and ventricular systolic/diastolic function, pulmonary artery systolic pressure (PASP), etc. We aim to evaluate the prognostic risk factors of patients with MR and construct a prognostic clinical model to guide clinical decision-making.

Conditions

Timeline

Start date
2016-06-15
Primary completion
2030-06-15
Completion
2030-06-15
First posted
2025-03-14
Last updated
2025-09-05

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06876883. Inclusion in this directory is not an endorsement.